Detalhe da pesquisa
1.
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Br J Haematol
; 204(4): 1243-1248, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38083865
2.
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.
Haematologica
; 108(9): 2542-2545, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36794509
3.
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases.
Am J Hematol
; 98(4): E76-E79, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655582
4.
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Am J Hematol
; 97(10): E377-E379, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35959963
5.
Integrating large language models in systematic reviews: a framework and case study using ROBINS-I for risk of bias assessment.
BMJ Evid Based Med
; 2024 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38383136
6.
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
Blood Cancer J
; 13(1): 122, 2023 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567878